We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
-5.12%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$6.23B
AUM Growth
-$401M
(-6.1%)
Cap. Flow
+$712M
Cap. Flow
% of AUM
11.42%
Top 10 Holdings %
Top 10 Hldgs %
46.21%
Holding
101
New
19
Increased
9
Reduced
3
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Janux Therapeutics
JANX
|
+$193M |
| 2 |
JBIO
Jade Biosciences
JBIO
|
+$189M |
| 3 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$104M |
| 4 |
LENZ
LENZ Therapeutics
LENZ
|
+$67.1M |
| 5 |
CNTB
Connect Biopharma Holdings
CNTB
|
+$66.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$92.3M |
| 2 |
Novavax
NVAX
|
+$81M |
| 3 |
IGMS
IGM Biosciences
IGMS
|
+$75.4M |
| 4 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$52.4M |
| 5 |
TG Therapeutics
TGTX
|
+$50.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.5% |
| 2 | Financials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.6B
| $895M | 14.37% |
6,806,341
+394,113
| +6% | +$52.5M |
|
|
2
Novavax
NVAX
$1.22B
| $543M | 8.72% |
2,559,918
-442,169
| -15% | -$81M |
|
|
FMTX
3
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $224M | 3.6% |
9,011,651
| – | – |
|
|
4
Janux Therapeutics
JANX
$921M
| $216M | 3.47% |
+8,670,644
| New | +$193M |
|
5
Vor Biopharma
VOR
$1.08B
| $207M | 3.33% |
556,049
| – | – |
|
|
JBIO
6
Jade Biosciences
JBIO
$1.2B
| $189M | 3.03% |
+236,114
| New | +$189M |
|
7
Nkarta
NKTX
$153M
| $178M | 2.85% |
5,605,129
| – | – |
|
8
MacroGenics
MGNX
$238M
| $160M | 2.56% |
5,943,594
+1,010,000
| +20% | +$29.6M |
|
|
CNTB
9
Connect Biopharma Holdings
CNTB
$130M
| $137M | 2.19% |
6,991,003
+3,999,795
| +134% | +$66.7M |
|
|
10
TG Therapeutics
TGTX
$8.35B
| $130M | 2.08% |
3,342,743
-1,293,403
| -28% | -$50.8M |
|
|
IMGN
11
DELISTED
Immunogen Inc
IMGN
| $121M | 1.95% |
18,417,458
| – | – |
|
12
Atea Pharmaceuticals
AVIR
$367M
| $115M | 1.85% |
5,368,451
| – | – |
|
|
ITOS
13
DELISTED
iTeos Therapeutics
ITOS
| $113M | 1.82% |
4,417,259
+1
| +0% | +$24 |
|
|
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
| $113M | 1.81% |
+4,965,588
| New | +$104M |
|
15
Axsome Therapeutics
AXSM
$11.9B
| $112M | 1.79% |
1,655,447
| – | – |
|
16
Phathom Pharmaceuticals
PHAT
$942M
| $105M | 1.69% |
3,115,008
| – | – |
|
17
Instil Bio
TIL
$48.9M
| $94.1M | 1.51% |
243,540
| – | – |
|
18
Rocket Pharmaceuticals
RCKT
$340M
| $93.3M | 1.5% |
2,107,149
| – | – |
|
|
ETNB
19
DELISTED
89bio
ETNB
| $92.9M | 1.49% |
4,965,769
+229,555
| +5% | +$5.12M |
|
|
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
| $91.3M | 1.47% |
5,283,976
| – | – |
|
21
Vaxcyte
PCVX
$7.68B
| $87M | 1.4% |
3,865,808
| – | – |
|
|
KNTE
22
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $83.6M | 1.34% |
3,593,052
| – | – |
|
|
LENZ
23
LENZ Therapeutics
LENZ
$178M
| $82.9M | 1.33% |
+385,481
| New | +$67.1M |
|
24
Travere Therapeutics
TVTX
$5.28B
| $81.9M | 1.31% |
5,614,428
| – | – |
|
25
Werewolf Therapeutics
HOWL
$23.1M
| $74.8M | 1.2% |
+4,291,881
| New | +$58.8M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, RA Capital Management held 101 positions worth $6.23B, down 6.1% from $6.63B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
RA Capital Management deployed $712M of net new capital in Q2 2021, opening 19 new positions and adding to 9 existing holdings. Its largest new stake was Janux Therapeutics: 8,670,644 shares worth $216M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Novavax, an estimated $81M trimmed.
- RA Capital Management's largest Q2 2021 buy was Janux Therapeutics: 8,670,644 shares worth $216M.
- RA Capital Management added most to Connect Biopharma Holdings in Q2 2021, an estimated $66.7M increase.
- RA Capital Management's biggest Q2 2021 reduction was Novavax, cutting an estimated $81M.
- RA Capital Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $92.3M.
- RA Capital Management's ten largest holdings make up 46% of its $6.23B portfolio in Q2 2021.
- RA Capital Management opened 19 new positions and closed 9 in Q2 2021.
- RA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $6.23B.
Based on RA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.